Case Study

Pharmagroup Int. and Fluvera: When subsidiary governance means losing competitive ground

9 pages
October 2006
Reference: IMD-3-1706

Pharmagroup Int. faces difficulties in finishing the development and getting to the market an new, strategically important product. The product was created by a US start up, that had originally formed a strategic Joint Venture with Pharmagroup, but was then more and more integrated into the group because of difficulties in R&D that Pharmagroup was unable to control and overcome. Now, R&D takes place in a fully owned US subsidiary but Pharmagroup is still unable to make considerable progress with the current governance system. The learning objective is to understand the importance of subsidiary governance and its business dimension in multinational groups, to identify key problems and causes in the setting and to design a subsidiary governance system for the US operations that leads to efficient and timely conclusion of development and market launch.

Corporate Governance, Subsidiary Company, Pharmaceuticals
Europe, United States of America
Healthcare, Pharmaceuticals
Generalized Experience
© 2006
Available Languages
Case clearing houses

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics